Ocugen pays $15 mn upfront to Bharat Biotech for Covaxin rights in Canada
Similar to the US arrangement, Ocugen will retain 45 per cent of the profit from sales of Covaxin in Canada.
Keep The Best In Your Boundary
Keep The Best In Your Boundary